{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:22:54Z","timestamp":1792174974149,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.anndiagpath.2025.152525","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:39:20Z","timestamp":1751942360000},"page":"152525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Analysis of clinicopathological and immunohistochemical features of pheochromocytoma\/paraganglioma"],"prefix":"10.1016","volume":"79","author":[{"given":"Ling-Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Chu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152525_bb0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of Paragangliomas and Pheochromocytomas [J]","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2025.152525_bb0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on Pheochromocytoma and Paraganglioma from the SSO endocrine\/head and neck disease-site work group. Part 1 of 2: advances in pathogenesis and diagnosis of Pheochromocytoma and Paraganglioma [J]","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152525_bb0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on Pheochromocytoma and Paraganglioma: toward a molecular classification [J]","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal Tumours in 2017 World Health Organization (WHO) of endocrine Tumours [J]","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score [J]","volume":"164","author":"Cho","year":"2018","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-21-0370","article-title":"Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery","volume":"186","author":"Parasiliti-Caprino","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152525_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of Pheochromocytoma and Paraganglioma and its clinical implications [J]","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152525_bb0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades [J]","volume":"107","author":"Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MED.0000000000000476","article-title":"Diabetes,, Obesity. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management [J]","volume":"26","author":"Hamidi","year":"2019","journal-title":"Current opinion in endocrinology, diabetes, obesity"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152525_bb0055","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anndiagpath.2025.152525_bb0060","first-page":"637","article-title":"A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology [J]","volume":"85","author":"Mantero","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.anndiagpath.2025.152525_bb0065","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/jnci\/djg024","article-title":"Pheochromocytoma: the expanding genetic differential diagnosis","volume":"95","author":"Bryant","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.anndiagpath.2025.152525_bb0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1500681","article-title":"Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients [J]","volume":"150","author":"Baguet","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2214\/ajr.185.3.01850684","article-title":"Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas","volume":"185","author":"Motta-Ramirez","year":"2005","journal-title":"AJR Am J Roentgenol"},{"issue":"9486","key":"10.1016\/j.anndiagpath.2025.152525_bb0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma [J]","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anndiagpath.2025.152525_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of Pheochromocytoma and Paraganglioma [J]","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.anndiagpath.2025.152525_bb0090","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators [J]","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.anndiagpath.2025.152525_bb0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.surg.2004.05.058","article-title":"Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas","volume":"136","author":"Shen","year":"2004","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.anndiagpath.2025.152525_bb0100","first-page":"305","article-title":"Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma","volume":"206","author":"Tavangar","year":"2010","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.anndiagpath.2025.152525_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081813","article-title":"Clinical and pathological tools for predicting recurrence and\/or metastasis in patients with Pheochromocytoma and Paraganglioma [J]","volume":"10","author":"Bima","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.anndiagpath.2025.152525_bb0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12022-020-09658-7","article-title":"What have we learned from molecular biology of Paragangliomas and Pheochromocytomas?","volume":"32","author":"Papathomas","year":"2021","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2025.152525_bb0115","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2016-3829","article-title":"Characteristics of pediatric vs adult Pheochromocytomas and Paragangliomas [J]","volume":"102","author":"Pamporaki","year":"2017","journal-title":"The Journal of clinical endocrinology metabolism"},{"issue":"11","key":"10.1016\/j.anndiagpath.2025.152525_bb0120","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.anndiagpath.2025.152525_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194758","article-title":"NOP10 analysis of telomere maintenance related genes reveals as a new metastatic-risk marker in pheochromocytoma\/paraganglioma [J]","volume":"13","author":"Monteagudo","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.anndiagpath.2025.152525_bb0130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2217\/epi.15.82","article-title":"Emerging roles of ATRX in cancer","volume":"7","author":"Watson","year":"2015","journal-title":"Epigenomics"},{"issue":"35","key":"10.1016\/j.anndiagpath.2025.152525_bb0135","doi-asserted-by":"crossref","first-page":"57414","DOI":"10.18632\/oncotarget.10598","article-title":"NETs: organ-related epigenetic derangements and potential clinical applications","volume":"7","author":"Cives","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.anndiagpath.2025.152525_bb0140","doi-asserted-by":"crossref","unstructured":"Marinoni, I, Kurrer, A, Vassella, E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors [J]. Gastroenterology, 2014, 146(2): 453\u201360.e5.","DOI":"10.1053\/j.gastro.2013.10.020"},{"issue":"6021","key":"10.1016\/j.anndiagpath.2025.152525_bb0145","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.anndiagpath.2025.152525_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913425000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:12:05Z","timestamp":1755825125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913425000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S1092913425000905"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152525","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of clinicopathological and immunohistochemical features of pheochromocytoma\/paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2025.152525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152525"}}